Anticoagulated patient needing scaling and two extractions
A 58-year-old man with non-valvular atrial fibrillation attends for treatment of Stage III periodontitis. He takes apixaban 5 mg twice daily and bisoprolol, with no other medication. The plan is quadrant subgingival instrumentation plus extraction of the mandibular right first molar (probing depth 10 mm, class III furcation, grade III mobility) and the maxillary right second premolar (vertical root fracture). His last apixaban dose was at 08:00; the appointment is booked for 14:00. Blood pressure is 138/84 mmHg, platelets 214 × 10⁹/L, and eGFR 62 mL/min/1.73 m². He has no personal or family history of bleeding disorder, no liver disease, and reports an uncomplicated extraction three years ago while taking apixaban. He has not had antibiotic prophylaxis previously and asks whether he should stop his tablets.
1. Should the apixaban be interrupted? Justify your answer with the pharmacology and current guidance, and state what you would do if the patient insisted on stopping it.
Read the worked answer
No, do not interrupt apixaban for this treatment.
Reasoning:
- Apixaban is a direct factor Xa inhibitor with a half-life of about 12 hours and peak effect 3–4 hours after dosing. A 14:00 appointment is roughly 6 hours after the 08:00 dose, which is not true trough but is acceptable for these procedures; the lowest bleeding risk window is 12–24 hours after the last dose.
- Guidelines for dental procedures consistently advise continuing direct oral anticoagulants for routine periodontal treatment and simple extractions, because local haemostatic measures control bleeding and interruption exposes the patient to thromboembolic stroke risk - a far larger harm than a manageable bleed.
- INR is not a valid monitoring test for apixaban; if a level is genuinely needed (renal impairment, extreme risk), a calibrated anti-Xa assay is used, but it is not required for routine care.
- eGFR 62 and platelets 214 are unremarkable; no dose adjustment is indicated for the dental procedure.
If the patient insists on stopping, do not agree to unilaterally alter a cardiology-prescribed drug. Explain the stroke risk, offer to contact his cardiologist or anticoagulation service, and document the discussion. If bleeding risk were judged unusually high (e.g. multiple surgical extractions, severe renal impairment), the agreed approach would be made in consultation with the prescriber - typically omitting a single dose rather than a drug holiday - and not by the dentist alone. Deferring treatment to a morning appointment 12+ hours after the evening dose is a reasonable alternative.
2. Describe your local haemostatic protocol and post-operative instructions. Explain your analgesic choice and how you would manage prolonged bleeding at home.
Read the worked answer
Intra-operative:
- Atraumatic technique: careful periosteal elevation, socket debridement, avoid tearing soft tissue, and consider a primary closure or sutures with a resorbable material.
- Local anaesthetic with a vasoconstrictor, infiltrations rather than blocks where possible.
- Haemostatic agent in the socket (oxidised cellulose or collagen sponge) plus figure-of-eight sutures; apply firm pressure with a gauze pack for at least 10–15 minutes and confirm haemostasis before discharge.
- Tranexamic acid 4.8% mouthwash, 10 mL rinsed for 2 minutes four times daily for 2 days, is a well-supported adjunct for oral bleeding in anticoagulated patients.
Post-operative instructions: no rinsing, spitting, smoking, hot drinks, or exercise for 24 hours; soft diet; gentle brushing away from the socket; no probing or instrumentation of the site.
Analgesia: avoid NSAIDs. Ibuprofen and other NSAIDs add to the antithrombotic effect, increase gastrointestinal bleeding risk, and interact pharmacologically with anticoagulants. Paracetamol is the first choice, with a clear maximum daily dose and a check that no other product contains paracetamol.
If bleeding recurs at home: bite firmly on clean gauze for 20 minutes; if still bleeding, use the tranexamic acid rinse and repeat pressure; if bleeding persists beyond 30–60 minutes, is brisk, or the patient feels faint, contact the clinic or attend emergency care. Record a contact number. The judgement being tested is that local measures plus preservation of anticoagulation is the standard of care, and that NSAID avoidance is a specific, examinable safety point.
3. Suppose this patient instead had a mechanical mitral valve and took warfarin with an INR of 3.3. How would your preparation and decisions differ, including regarding antibiotic prophylaxis?
Read the worked answer
Anticoagulation. Warfarin management differs from DOAC management because a validated test exists. Check INR within 24–72 hours of the procedure; a simple extraction in a patient with INR ≤3.5 is generally safe with local haemostatic measures, and warfarin should not be stopped. An INR of 3.3 therefore does not mandate cancellation, but it should be rechecked on the day if the reading is older than 72 hours, and the procedure should be planned with the same local measures described earlier. If the INR were markedly elevated, or the surgery more extensive, the anticoagulation service would be consulted before proceeding. Never stop warfarin unilaterally: rebound hypercoagulability and valve thrombosis are serious risks.
Antibiotic prophylaxis. This is where the scenario changes fundamentally. A mechanical heart valve is a high-risk cardiac condition for infective endocarditis, so antibiotic prophylaxis is indicated for procedures involving gingival manipulation or perforation of the oral mucosa - including subgingival instrumentation and extractions. A single oral dose is given 30–60 minutes before the procedure, with regimen and allergy status checked. For the original apixaban patient with atrial fibrillation and no valve prosthesis, prophylaxis is not indicated; atrial fibrillation alone is not a qualifying cardiac condition, and unnecessary antibiotics carry their own risk.
Summary of the differences: the warfarin patient requires an INR check and endocarditis prophylaxis; the apixaban patient requires neither. Both require local haemostasis and NSAID avoidance.